Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
13 oct. 2023 16h30 HE | Travere Therapeutics, Inc.
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for...
clene-logo@2x.png
Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting
01 avr. 2022 07h00 HE | Clene, Inc.
SALT LAKE CITY, April 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...